AstraZeneca said it will stop manufacturing the Covid-19 vaccine to remove it from the world market. In a statement, the pharmaceutical company said that the measure is for commercial reasons, as there is a “surplus of immunizers” that have been updated for new variants of the disease. As a result, there was a decline in demand for the item.
+ Covovax: Anvisa approves new vaccine against Covid-19
Vaxzevria, developed in partnership with the University of Oxford, was one of the first vaccines against Covid-19 in the world. In Brazil, the vaccine was approved for registration by the National Health Surveillance Agency (Anvisa) in March 2021. At the time, the doses were also manufactured by the Oswaldo Cruz Foundation (Fiocruz).
According to independent estimates from AstraZeneca, more than 3 billion doses of the vaccine have been supplied worldwide since the first application, carried out in the United Kingdom, on January 4, 2021. Since April 2023, however, searches for Vaxzevria fell, damaging the revenue generated for the pharmaceutical company.
+ Covid-19 pandemic reduced life expectancy in Brazil by 2.8 years
“We are incredibly proud of the role Vaxzevria played. Our efforts have been recognized by governments around the world and are widely considered to be a critical component in ending the pandemic,” AstraZeneca said. “We will partner with regulatory authorities around the world to initiate the withdrawal of Vaxzevria’s marketing authorization,” he added.
Tags: AstraZeneca stops manufacturing vaccine Covid19 drop demand
